WCM Global Growth Limited (ASX:WQG) Declares Increased Dividend
WCM Global Growth Limited (ASX:WQG) declares a fully franked dividend of 1.89c per share for Q3 FY2025 and outlines a progressive dividend policy.
Orora Limited (ASX:ORA) Releases Investor Update
Orora Limited (ASX:ORA) announces strategic transformation and capital allocation plans, positioning for strong growth and shareholder returns.
Navigator Global Investments (ASX:NGI) Upgrades FY25 Earnings Outlook
Navigator Global Investments (ASX:NGI) upgrades FY25 earnings outlook, expecting Adjusted EBITDA to increase by 17-22%.
EDU Holdings Limited (ASX:EDU) Reports Record FY24 and Proposes Delisting
EDU Holdings (ASX:EDU) reports record FY24 revenue and profitability while proposing to delist from the ASX.
Treasury Wine Estates (ASX:TWE) Appoints Sam Fischer as New CEO
Treasury Wine Estates (ASX:TWE) appoints Sam Fischer as new CEO, succeeding Tim Ford after a 14-year tenure.
Errawarra Resources Ltd (ASX:ERW) Announces High-Grade Silver Results
Errawarra Resources (ASX:ERW) reports multiple high-grade silver results up to 920g/t, highlighting significant exploration potential at Elizabeth Hill.
Brightstar Resources (ASX:BTR) Advances Production and Development Programs
Brightstar Resources (ASX:BTR) begins its second ore processing campaign and advances the development of the Fish underground mine, aiming for increased gold production.
Bayan Mining and Minerals Ltd (ASX:BMM) Announces Gold Sampling at Bayan Springs
Bayan Mining and Minerals Ltd (ASX:BMM) confirms high-grade gold potential at Bayan Springs, Nevada, validating its Carlin-style mineralization model.
Austco Healthcare Limited (ASX:AHC) Secures $2.1M Contract with Toronto Western Hospital
Austco Healthcare (ASX:AHC) secures a $2.1M contract to implement its nurse call platform at Toronto Western Hospital, enhancing its North American presence.
Lumos Diagnostics (ASX:LDX) Secures Largest FebriDx Purchase Order with iMedical
Lumos Diagnostics (ASX:LDX) announces its largest purchase order for FebriDx, reflecting increased US adoption and market acceptance.